Pacira BioSciences (PCRX) – Analyst Comments
-
JPMorgan Assumes Pacira Pharmaceuticals (PCRX) at Overweight, 'Shares Well Positioned Ahead of Catalysts'
-
TD Cowen Upgrades Pacira Pharmaceuticals (PCRX) to Outperform, 'Anticipate Sentiment Reversal In 2H23'
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Back to PCRX Stock Lookup